JPMorgan Chase & Co. restated their overweight rating on shares of AstraZeneca (LON:AZN) in a report issued on Friday, October 19th. They currently have a GBX 6,500 ($84.93) price objective on the biopharmaceutical company’s stock.
Other analysts have also issued reports about the stock. Shore Capital restated a hold rating on shares of AstraZeneca in a report on Tuesday, July 24th. Deutsche Bank reiterated a buy rating and set a GBX 6,000 ($78.40) price target on shares of AstraZeneca in a research note on Friday, July 27th. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research note on Monday, September 24th. Jefferies Financial Group boosted their price target on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 6,050 ($79.05) and gave the stock a buy rating in a research note on Friday, July 13th. Finally, UBS Group reiterated a neutral rating and set a GBX 5,600 ($73.17) price target on shares of AstraZeneca in a research note on Monday, July 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of GBX 5,831.89 ($76.20).
Shares of LON AZN traded up GBX 79 ($1.03) during trading on Friday, hitting GBX 6,172 ($80.65). 2,861,442 shares of the company were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 12-month low of GBX 4,260 ($55.66) and a 12-month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is Cost of Capital?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.